NextFin news, On October 17, 2025, at a White House event focused on fertility treatments and prescription drug costs, President Donald Trump announced his administration’s intention to slash the price of Ozempic, a leading GLP-1 receptor agonist used for weight loss and diabetes management, to $150 per month. This represents a dramatic reduction from the current list price of around $1,000. Trump clarified that his comments specifically targeted Ozempic, emphasizing that prices for this “fat-loss drug” would be significantly lowered.
The announcement, made in Washington D.C., came amid ongoing negotiations under the Trump administration’s revived “Most Favored Nation” (MFN) drug pricing policy, which aims to align U.S. pharmaceutical prices with those paid by other wealthy nations. This policy has already led to price concessions from major pharmaceutical companies such as Pfizer and AstraZeneca through direct-to-consumer platforms like “TrumpRx.”
Following the announcement, shares of Novo Nordisk, the manufacturer of Ozempic, fell more than 6%, while Eli Lilly, a competitor in the GLP-1 market, saw its stock drop nearly 4%. Other biotech firms involved in obesity and diabetes treatments, including Zealand Pharma and Viking Therapeutics, also experienced declines. Both Novo Nordisk and Eli Lilly confirmed ongoing discussions with the administration but declined to comment on specific pricing agreements.
Market analysts interpret Trump’s $150 price target as aspirational and potentially a strategic negotiation tactic rather than a finalized policy. Bernstein analysts noted that the figure is not yet set in stone, and investors appear to be pricing in a worst-case scenario. The administration’s promise of “swift negotiations” has left stakeholders—ranging from investors to clinicians and patients—watching closely for further developments.
The proposed price cut reflects broader political and economic pressures to address the high cost of prescription drugs in the U.S., which remains significantly above prices in comparable developed countries. According to the IQVIA Institute, U.S. drug spending per capita was approximately $1,600 in 2024, nearly double that of other OECD nations. Ozempic’s high cost has been a barrier to access for many patients, despite its proven efficacy in managing obesity and type 2 diabetes, conditions affecting over 100 million Americans combined.
Reducing Ozempic’s price to $150 monthly could dramatically improve affordability and adherence, potentially reducing long-term healthcare costs associated with obesity-related complications such as cardiovascular disease and diabetes-related hospitalizations. However, pharmaceutical companies argue that high prices fund ongoing research and development (R&D) for innovative therapies. Novo Nordisk reported R&D expenses of $2.3 billion in 2024, underscoring the financial stakes involved.
The market reaction underscores investor concerns about profit margin compression in the lucrative GLP-1 segment, which has seen explosive growth. Novo Nordisk’s GLP-1 sales reached $12 billion in 2024, representing over 40% of its total revenue. A mandated price cut to $150 per month could reduce revenue by up to 85%, assuming current volume remains constant, forcing companies to reassess their pricing strategies and pipeline investments.
From a policy perspective, the MFN approach and Trump’s aggressive pricing targets signal a potential paradigm shift in U.S. drug pricing regulation. If successfully implemented, this could catalyze broader reforms across other high-cost drug categories, encouraging pharmaceutical companies to adopt more globally competitive pricing models. However, the complexity of negotiations and potential legal challenges from industry stakeholders suggest a protracted process ahead.
Looking forward, the administration’s strategy may accelerate the adoption of alternative payment models, such as value-based pricing and expanded use of biosimilars, to balance affordability with innovation incentives. Additionally, increased transparency in drug pricing and supply chain costs could emerge as key policy tools.
For patients and healthcare providers, a lower Ozempic price could enhance treatment accessibility and adherence, improving public health outcomes in obesity and diabetes management. However, the transition period may involve supply chain adjustments and market uncertainty, requiring careful stakeholder coordination.
In conclusion, President Trump’s $150 Ozempic price proposal has ignited significant market volatility and reignited the national conversation on pharmaceutical pricing reform. While the proposal remains under negotiation, its implications for drug manufacturers, investors, patients, and policymakers are profound, potentially reshaping the U.S. pharmaceutical landscape in the coming years.
According to Medical Economics, the announcement is part of a broader administration effort to leverage the MFN policy to bring U.S. drug prices closer to international levels, with ongoing discussions but no finalized agreements yet. The market’s reaction reflects both the uncertainty and the high stakes involved in this evolving policy environment.
Explore more exclusive insights at nextfin.ai.
